What is the history of Hemicrania Continua?

Hemicrania Continua is a rare, strictly unilateral headache disorder characterized by continuous pain with exacerbations. First formally described in the early 1980s, the clinical understanding of Hemicrania Continua has evolved from a mysterious chronic condition to a well-defined entity uniquely responsive to the anti-inflammatory drug indomethacin.

Who first discovered Hemicrania Continua?

The clinical characterization of Hemicrania Continua was spearheaded by Dr. Jes Olesen and colleagues in 1981. While isolated cases of persistent unilateral headaches had been reported sporadically throughout the 20th century, Olesen’s work provided the definitive diagnostic criteria that allowed clinicians to distinguish it from other primary headache disorders like cluster headaches or hemicrania paroxystica.

How has the understanding of Hemicrania Continua evolved?

Initially, many patients were misdiagnosed with chronic tension-type headaches or migraines. The turning point in our understanding came with the realization that Hemicrania Continua is an "indomethacin-responsive headache." This unique sensitivity is so central to the diagnosis that it remains a cornerstone of the International Classification of Headache Disorders (ICHD) criteria. Modern neuroimaging, specifically functional MRI and PET scans, has further helped researchers map the hypothalamic activation patterns associated with the disorder.

What are the major milestones in treatment and advocacy?

The history of Hemicrania Continua treatment is defined by the discovery of indomethacin’s efficacy. However, because this medication can have significant gastrointestinal side effects, the focus has shifted to identifying alternative therapies. Evolution in the field includes:

• 1981: Formal medical description and naming of the condition by Dr. Jes Olesen.


• 1988: Inclusion in the first edition of the ICHD classification.


• 2000s–Present: Integration of patient-led advocacy, including the 86 members of the DiseaseMaps.org community who share lived experiences to help researchers identify early warning signs and treatment tolerances.

How has technology changed our view of Hemicrania Continua?

While Hemicrania Continua is not currently classified as a genetic disease, advances in genetic sequencing have allowed researchers to rule out hereditary syndromes that mimic its symptoms. Today, high-resolution imaging helps differentiate the disease from secondary causes like structural lesions or tumors, ensuring that patients receive timely and accurate care.

Next steps

• Consult a board-certified neurologist or headache specialist to confirm your diagnosis via a supervised indomethacin trial.


• Join the Hemicrania Continua community on DiseaseMaps.org to connect with others who understand the burden of chronic, unilateral pain.


• Maintain a detailed headache diary to track your responses to medications and potential environmental triggers.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• International Headache Society (IHS), ICHD-3 criteria for Hemicrania Continua.


• NIH Genetic and Rare Diseases Information Center (GARD).


• Orphanet: Rare disease database for persistent unilateral headache disorders.


• PubMed: Longitudinal clinical reviews on indomethacin-responsive headaches.